Compare AZZ & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AZZ | NAMS |
|---|---|---|
| Founded | 1956 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.1B |
| IPO Year | 1994 | N/A |
| Metric | AZZ | NAMS |
|---|---|---|
| Price | $146.58 | $35.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $141.80 | $46.75 |
| AVG Volume (30 Days) | 320.3K | ★ 1.1M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.58% | N/A |
| EPS Growth | ★ 486.59 | N/A |
| EPS | ★ 1.72 | N/A |
| Revenue | ★ $1,061,817,000.00 | N/A |
| Revenue This Year | $7.03 | $17.96 |
| Revenue Next Year | $4.25 | $540.65 |
| P/E Ratio | $81.91 | ★ N/A |
| Revenue Growth | ★ 14.53 | N/A |
| 52 Week Low | $92.98 | $20.53 |
| 52 Week High | $162.20 | $42.21 |
| Indicator | AZZ | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 47.29 | 57.72 |
| Support Level | $131.08 | $33.83 |
| Resistance Level | $151.67 | $37.27 |
| Average True Range (ATR) | 6.45 | 1.74 |
| MACD | -1.72 | 0.42 |
| Stochastic Oscillator | 38.24 | 71.19 |
AZZ Inc is a provider of galvanizing and coil coating solutions to a broad range of end markets in North America. The company's operating segment consists of AZZ Metal Coatings, AZZ Precoat Metals, and AZZ Infrastructure Solutions. The company generates the majority of its revenue from the Precoat Metals segment, which provides coil coating application of protective and decorative coatings and related value-added downstream processing for steel and aluminum coils. Geographically, the company operates in the United States and Canada.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.